甘李藥業(603087.SH):門冬胰島素30注射液(非最終滅菌產品)檢查結果符合GMP標準
格隆匯3月12日丨甘李藥業(603087.SH)公佈,近日,公司收到北京市藥品監督管理局核准簽發的門冬胰島素30注射液(非最終滅菌產品)《藥品GMP符合性檢查結果的通知》。
截至本公吿發布之日,在全球市場該產品只有諾和諾德一家生產。根據諾和諾德2019年年報,預混門冬胰島素注射液2019年在全球的銷售額為95.85億丹麥克朗,在中國的銷售額約為43.02億丹麥克朗。
本次門冬胰島素30注射液(非最終滅菌產品)為原有車間增加品種認證。本次《關於藥品GMP符合性檢查結果的通知》的獲得,表明公司相關生產線滿足GMP要求,將有利於公司提供符合質量要求的產品的能力,以滿足市場需求。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.